118
Y. Zhang et al. / Carbohydrate Research 361 (2012) 114–119
90-O-b-
D
-glucopyranoside25 except for a downfield shift at C-30, to-
3.4. Identification
gether with the occurrence of an additional glucosyl unit, which
suggested 7 to be lyoniresinol 90-O-b-
D
-glucopyranosyl(1?3)-b-
D
-
3.4.1. Pteleifoside A (1)
glucopyranoside. The HMBC cross-peaks (Fig. 1) of H-70 with C-5,
C-20, and C-90, H-100 with C-90, and H-1000 with C-300 confirmed such
a planar structure. The absolute configuration of 7 was established
as 70S,8R,80R based on the same CD orientations at 242, 274, and
White amorphous powder (MeOH); ½a D22
ꢀ61.5 (c 0.13, MeOH);
ꢂ
IR (KBr) mmax 3411, 2972, 2933, 1637, 1452, 1383, 1257, 1130,
1070, 1043, 987, 642 cmꢀ1 1H NMR (500 MHz, CD3OD), and 13C
;
NMR (125 MHz, CD3OD) data, see Tables 1 and 2; ESI-MS m/z (po-
sitive) 561 [M+Na]+, (negative) 1075 [2MꢀH]ꢀ; HR-ESI-MS m/z
561.2891 [M+Na]+ (calcd for C25H46O12Na, 561.2887).
286 nm with that of (+)-lyoniresinol 90-O-b-
D
-glucopyranoside
(10).25 Therefore, 7 was elucidated to be (+)-lyoniresinol 90-O-b-
-glucopyranosyl(1?3)-b- -glucopyranoside.
D
D
3.4.2. Pteleifoside B (2)
White amorphous powder (MeOH); ½a D22
ꢂ
ꢀ66.5 (c 0.2, MeOH);
3. Experimental
IR (KBr) mmax 3415, 2967, 2927, 1639, 1454, 1381, 1259, 1130,
1043, 814, 636 cmꢀ1 1H NMR (500 MHz, CD3OD), and 13C NMR
;
3.1. General experimental procedures
(125 MHz, CD3OD) data, see Tables 1 and 2; ESI-MS m/z (positive)
543 [M+Na]+, (negative) 1039 [2MꢀH]ꢀ; HR-ESI-MS m/z 543.2783
[M+Na]+ (calcd for C25H44O11Na, 543.2781).
Optical rotations were determined on a Perkin–Elmer 341
polarimeter. CD curves were obtained on a Jasco J-810 spectropo-
larimeter. IR spectra were recorded on a Nicolet Magna-750-FTIR
spectrometer with KBr tablet. NMR spectra were acquired on a
Bruker AM-400 or a Bruker AV-500 spectrometer. ESI-MS and
HR-ESI-MS were obtained on an Esquire 3000plus and a Q-TOF-Ul-
tima mass spectrometer, respectively. Semipreparative HPLC was
carried out on a Waters 515 pump with a Waters 2487 (UV) detec-
3.4.3. Pteleifoside C (3)
White amorphous powder (MeOH);
MeOH); IR (KBr) mmax 3417, 2927, 1940, 1664, 1457, 1365, 1245,
1070, 819 cmꢀ1 1H NMR (500 MHz, pyridine-d5) d 6.15 (1H, s, H-
½
a 2D5
ꢂ
ꢀ110.3 (c 0.31,
;
8), 5.69 (1H, d, J = 2.2 Hz, H-100), 5.09 (1H, d, J = 7.7 Hz, H-10), 4.74
(1H, d, J = 2.2 Hz, H-200), 4.67 (1H, br d, J = 10.5 Hz, H-60a), 4.60
(1H, d, J = 9.3 Hz, H-400a), 4.37 (1H, d, J = 9.3 Hz, H-400b), 4.19 (2H,
s, H2-500), 4.18 (1H, dd, J = 9.3, 8.9 Hz, H-30), 4.04 (1H, dd, J = 10.6,
6.2 Hz, H-60b), 4.01–3.93 (3H, m, H-20, H-40 and H-50), 3.00 (1H,
br d, J = 13.3 Hz, H-4a), 2.27 (1H, br d, J = 12.6 Hz, H-2a), 2.21
(3H, s, Me-10), 1.77 (1H, dd, J = 13.5, 11.4 Hz, H-4b), 1.74 (3H, s,
Me-12), 1.71 (3H, s, Me-13), 1.22 (3H, s, Me-11); 1H NMR
(400 MHz, CD3OD), and 13C NMR (100 MHz, CD3OD or 125 MHz,
pyridine-d5) data, see Tables 1 and 2; ESI-MS m/z (positive) 541
[M+Na]+, (negative) 563 [M+HCOO]ꢀ, 1035 [2MꢀH]ꢀ; HR-ESI-MS
m/z 541.2270 [M+Na]+ (calcd for C24H38O12Na, 541.2261).
tor and a Kromasil 100-5-C18 column (250 ꢁ 10 mm, 5
lm). D-
1400 macroporous resin (Yangzhou Pharmaceutical Factory,
Yangzhou, China), Rp-18 reversed phase silica gel (150–200 mesh,
Fuji Silysia Chemical LTD, Aichi, Japan), MCI gel (CHP20P, 75–
150 lm, Mitsubishi Chemical Industries Ltd, Tokyo, Japan), and
Sephadex LH-20 gel (Pharmacia Biotech AB, Uppsala, Sweden)
were used for column chromatography (CC), and precoated silica
gel GF254 plates (Qingdao Haiyang Chemical Plant, Qingdao, Chi-
na) were used for TLC. All solvents used were of analytical grade
(Shanghai Chemical Plant, Shanghai, China).
3.2. Plant material
3.4.4. Pteleifoside D (4)
White amorphous powder (MeOH); ½a D25
ꢀ20.4 (c 0.43, MeOH);
ꢂ
The roots and rhizomes of M. pteleifolia were purchased from
Bozhou Chinese Materia Medica Market, Bozhou, Anhui Province,
P.R. China, in July 2009, which was identified by Professor Da-Yuan
Zhu of Shanghai Institute of Materia Medica. A voucher specimen
(No. 09-1008) was deposited with the Herbarium of Shanghai
Institute of Materia Medica.
CD (MeOH) kmax
(D
e
) 188 (ꢀ17.8), 205 (+54.1) nm; IR (KBr) mmax
3405, 2933, 1646, 1384,1319, 1216, 1049, 823 cmꢀ1 1H NMR
;
(400 MHz, CD3OD), and 13C NMR (100 MHz, CD3OD) data, see Ta-
bles 1 and 2; ESI-MS m/z (positive) 485 [M+Na]+, (negative) 461
[MꢀH]ꢀ, 923 [2MꢀH]ꢀ; HR-ESI-MS m/z 485.2001 [M+Na]+ (calcd
for C21H34O11Na, 485.1999).
3.3. Extraction and isolation
3.4.5. Pteleifoside E (5)
White amorphous powder; ½a D25
ꢂ
ꢀ74.3 (c 0.075, MeOH); IR (KBr)
1H NMR
Dried roots and rhizomes of M. pteleifolia (5 kg) were powdered
and extracted with 95% ethanol at room temperature three times.
After removal of the solvents by evaporation, the extract was sus-
pended in H2O and then partitioned successively with petroleum
ether, EtOAc, and n-BuOH. The n-BuOH-soluble part (180 g) was
subjected to macroporous resin column chromatography (CC, i.d.
10 ꢁ 80 cm) with gradient EtOH/H2O (0%, 20%, 50%, 75%, and
95%, v/v) as eluant to give fractions A–E. Fraction C (30% EtOH frac-
tion, 65 g) was separated by CC of MCI gel (MeOH/H2O 0%, 20%,
40%, 60%, and 95%, v/v) to afford sub-fractions B1-B5. Fr. B4 was
purified by CC of Rp-18 (MeOH/H2O, 50%) and Sephadex LH-20
(MeOH) to obtain 8 (20 mg), 9 (18 mg), 10 (34 mg), 16 (18 mg),
and 17 (52 mg); Fr. B3 was isolated by CC of Rp-18 (MeOH/H2O,
20–60%) and Sephadex LH-20 (MeOH/H2O, 75%) to furnish 3
(118 mg), 4 (36 mg), and 14 (30 mg); Fr. B2 was separated by CC
of Rp-18 (MeOH/H2O, 10–50%) and Sephadex LH-20 (MeOH/H2O,
50%) to offer 7 (77 mg), 6 (19 mg), and 13 (18 mg). Semiprepared
HPLC was applied to isolate 15 (9 mg, CH3OH/H2O, 50%) from Fr.
B4, 2 (9 mg, CH3OH/H2O, 40%) from Fr. B3, and 1 (8 mg, CH3OH/
H2O, 25%), 5 (9 mg, CH3OH/H2O, 20%), 11 (3 mg, CH3OH/H2O,
20%), and 12 (6 mg, CH3OH/H2O, 20%) from Fr. B2.
mmax 3404, 2932, 1603, 1516, 1272, 1051, 822 cmꢀ1
.
(400 MHz, CD3OD) and 13C NMR (100 MHz, CD3OD) data, see Table
3; ESI-MS (positive) m/z (positive) 485 [M+Na]+, (negative) 461
[MꢀH]ꢀ, 923 [2MꢀH]ꢀ; HR-ESI-MS m/z 485.1639 [M+Na]+ (calcd
for C20H30O12Na, 485.1635).
3.4.6. Pteleifoside F (6)
White amorphous powder; ½a D25
ꢀ22.1 (c 0.26, MeOH); IR (KBr)
ꢂ
mmax 3415, 2927, 1641, 1519, 1467, 1261, 1166, 1083, 833 cmꢀ1
;
CD (MeOH) kmax
(
D
e
) 216 (+115.1), 231 (ꢀ4.8), 252 (+24.0), 290
(ꢀ113.9), 329 (+42.5) nm; 1H and 13C NMR (400 and 100 MHz,
CD3OD) data, see Table 3; ESI-MS (positive) m/z (positive) 605
[M+Na]+, (negative) 581 [MꢀH]ꢀ; HR-ESI-MS m/z 605.1468
[M+Na]+ (calcd for C26H30O15Na, 605.1482).
3.4.7. Pteleifoside G (7)
White amorphous powder; ½a D25
ꢂ
+50.5 (c 0.05, MeOH); CD
(MeOH) kmax
(
D
e
) 206 (+248.6), 215 (ꢀ129.6), 243 (+110.7), 274
(+31.0), 286 (ꢀ10.0) nm; 1H and 13C NMR (400 and 100 MHz,
CD3OD) data, see Table 3; ESI-MS m/z (positive) 767 [M+Na]+,